Unaudited Pro Forma Condensed Combined Statement of Operations. For the Year Ended December 31, 2019 (In thousands, except per share amounts) OrthoPediatrics Corp. Vilex Companies Subtotal OrthoPediatrics Corp. Pro Forma Total OrthoPediatrics Corp. Historical Historical Pro Forma Pro Forma Preliminary Pro Forma Vilex Divestiture Pro Forma December 31, 2019 January 1 - March 31, 2019 April 1 - June 4, 2019 Financing Adjustments Acquisition Adjustments Combined Adjustments Combined Net revenue $ 72,552 $ 2,761 $ 1,749 $ — $ — $ 77,062 $ (2,574) $ 74,488 Cost of revenue 17,933 643 2 672 — — 19,248 (885) 18,363 Gross profit 54,619 2,118 1,077 — — 57,814 (1,689) 56,125 Operating expenses: Sales and marketing 31,284 769 554 — — 32,607 (982) 31,625 General and administrative 26,664 733 2 513 — (180) 4(a) 27,730 (1,154) 26,576 Research and development 5,748 20 2 71 — — 5,839 (24) 5,815 Total operating expenses 63,696 1,522 1,138 — (180) 66,176 (2,160) 64,016 Operating income (loss) (9,077) 596 (61) — 180 (8,362) 471 (7,891) Other expenses (income): Interest expense (income) 3,538 66 69 1,588 4(b) (135) 4(b) 5,126 — 5,126 Other expense 70 — — — — 70 — 70 Total other expenses (income) 3,608 66 69 1,588 (135) 5,196 — 5,196 Net income (loss) from continuing operations $ (12,685) $ 530 $ (130) $ (1,588) $ 315 $ (13,558) $ 471 $ (13,087) Net gain from discontinued operations $ (1,046) $ — $ — $ — $ — $ (1,046) $ — $ (1,046) Net income (loss) $ (13,731) $ 530 $ (130) $ (1,588) $ 315 $ (14,604) $ 471 $ (14,133) Net income (loss) attributable to common stockholders $ (13,731) $ 530 $ (130) $ (1,588) $ 315 $ (14,604) $ 471 $ (14,133) Weighted average common shares - basic and diluted 14,624,194 14,727,712 4(c) Net loss from continuing operations per share attributable to common stockholders - basic and diluted $ (0.87) $ (0.89) Net loss from discontinued operations per share attributable to common stockholders - basic and diluted $ (0.07) $ (0.07) Net loss per share attributable to common stockholders - basic and diluted $ (0.94) $ (0.96) See accompanying notes to unaudited pro forma condensed combined financial information. OrthoPediatrics Corp. Unaudited Pro Forma Condensed Combined Statement of Operations For the Year Ended December 31, 2018 (In thousands, except per share amounts) OrthoPediatrics Corp. Vilex Companies Subtotal OrthoPediatrics Corp. Pro Forma Total OrthoPediatrics Corp. Historical Historical Pro Forma Pro Forma Preliminary Pro Forma Vilex Divestiture Pro Forma December 31, 2018 December 31, 2018 Financing Adjustments...
Unaudited Pro Forma Condensed Combined Statement of Operations. (l) Represents reclassifications to conform to our basis of presentation for our statement of operations, which have no effect on the net income of Cook Pharmica, and relate to:
Unaudited Pro Forma Condensed Combined Statement of Operations. For the Year Ended December 31, 2019 (in thousands except for share and per share information) Athena for the Period from January 1, 2019 to March 27, 2000 Xxxxxxx X Shipping Inc. for the Year Ended December 31, 2019 Pro Forma Adjustments Notes Pro Forma Combined Total revenues $ 46,454 $ 579,784 $ (95) (1) $ 626,143 Voyage expenses 12,722 230,675 — 243,397 Vessel operating expenses 13,208 153,662 — 166,870 Vessel operating expenses-related party 2,081 — — 2,081 General and administrative expenses 690 29,451 — 30,141 Loss on sale of vessels — 18,344 — 18,344 Depreciation and amortization 9,630 108,703 (2,621 ) (2) 115,712 Operating income 8,123 38,949 2.526 49,598 Other (expense)/income, net Interest expense (3,187 ) (46,772 ) (540 ) (3) (50,499 ) Other income 44 (2,259 ) — (2,215 ) Total other expense, net (3,143 ) (49,031 ) (540 ) (52,714 ) Net income/(loss) 4,980 (10,082 ) 1,986 (3,116 ) Less: Net income attributable to noncontrolling interest — (776 ) — (776 ) Net income (loss) attributable to the Company’s shareholders $ 4,980 $ (9,306 ) $ 1,986 $ (2,340 ) Weighted average shares outstanding — basic and diluted 39,890,696 Loss per share $ (0.06 ) Notes to Unaudited Pro Forma Condensed Combined Financial Information (dollars in thousands)
Unaudited Pro Forma Condensed Combined Statement of Operations. For the Year Ended June 30, 2017 (dollars in millions, except per share data) Catalent Cook Pharmica (Note 1) Reclassifications(l) Financing Transactions Acquisition Pro Forma Net revenue $ 2,075.4 $ 179.0 $ 1.3 $ — $ — $ 2,255.7 Cost of sales 1,420.8 119.4 1.4 — 1.1 (m) 1,542.7 Gross margin 654.6 59.6 (0.1 ) — (1.1 ) 713.0 Selling, general and administrative expenses 402.6 21.6 4.5 — 14.6 (n),(o) 443.3 Research and development — 1.1 (1.1 ) — — Corporate Allocation — 3.1 (3.1 ) — — Restructuring and other 8.0 — — — — 8.0 Operating earnings 234.2 33.8 (0.4 ) — (15.7 ) 251.9 Interest expense, net 90.1 — — 32.5 (p) — 122.6 Other (income)/expense, net 8.5 — (0.4 ) — — 8.1 Earnings from continuing operations before income taxes 135.6 33.8 — (32.5 ) (15.7 ) 121.2 Income tax expense/(benefit) 25.8 (110.4 )(q) — (12.7 )(q) (6.1 )(q) (103.4 ) Net earnings $ 109.8 $ 144.2 $ — $ (19.8 ) $ (9.6 ) $ 224.6 Earnings per share attributable to Catalent Basic Net earnings $ 0.88 $ 1.71 (r) Diluted Net earnings 0.87 1.69 (r) See accompanying notes to unaudited pro forma condensed combined financial statements. Notes to the Unaudited Pro Forma Condensed Combined Financial Statements
Unaudited Pro Forma Condensed Combined Statement of Operations. The following adjustments were made in the preparation of the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022:
Unaudited Pro Forma Condensed Combined Statement of Operations. (G) Revenues and Cost of revenues Adjustments have been included in the unaudited pro forma condensed combined statement of operations to eliminate revenues and cost of revenues from transactions between Express Scripts and Medco. Express Scripts’ and Medco’s pharmacies may be included in the pharmacy networks of the other respective company in order to fulfill members’ prescriptions for certain drugs that are under limited or exclusive distribution contracts with manufacturers.
Unaudited Pro Forma Condensed Combined Statement of Operations. We prepared the following unaudited pro forma condensed combined statement of operations based on the historical consolidated statement of operations of CareCloud, Inc. (“CareCloud”, formerly MTBC, Inc.) as adjusted to give effect to the following transaction (the “Transaction”): ● Our acquisition of Meridian Billing Management Co. and Origin Holdings, Inc. (collectively, “Meridian”), which consists of all of the assets and liabilities of Meridian with an effective date of June 16, 2020. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2020 gives effect to the Transaction as if it had occurred on January 1, 2020. We did not include the operating results for CareCloud Health, Inc., fka CareCloud Corporation, in the unaudited pro forma condensed combined statement of operations since such amounts are included in the CareCloud Inc. financial results for substantially the entire year. The pro forma condensed combined statement of operations includes adjustments for our acquisition under Article 11 of Regulation S-X. The results of the Transaction are shown for the period prior to their acquisition by XxxxXxxxx. We determined that the Transaction involved the acquisition of a business, and considering the guidance in Rule 11-01(d) of Regulation S-X, met the significance test of Rule 8-04 of Regulation S-X. We have based the pro forma adjustments upon available information and certain assumptions that we believe are reasonable under the circumstances. We describe in greater detail the assumptions underlying the pro forma adjustments in the accompanying notes, which you should read in conjunction with this unaudited pro forma condensed combined statement of operations. In many cases, we based these assumptions on estimates. The actual adjustments to our audited consolidated financial statements will depend upon a number of factors. Accordingly, the actual adjustments that will appear in our consolidated financial statements will differ from these pro forma adjustments, and those differences may be material. We account for our acquisition using the acquisition method of accounting for business combinations under generally accepted accounting principles used in the United States (“GAAP”), with CareCloud being considered the acquiring entity. Under the acquisition method of accounting, the total consideration paid is allocated to an acquired company’s tangible and intangible assets, net of liabilities, based on their...
Unaudited Pro Forma Condensed Combined Statement of Operations. For the Three Months Ended March 31, 2016 (In thousands of U.S. Dollars, except per share data) Historical Spark Major Energy Companies Reclassification Acquisition Adjustments Spark Pro Forma Revenues: — Retail revenues $ 110,019 $ — $ 51,144 (d) $ — $ 161,163 Sale of natural gas and electricity — 51,144 (51,144 ) (d) — — Net asset optimization 527 — — — 527 Total revenues 110,546 51,144 — — 161,690 Operating expenses: Retail cost of revenues 68,800 — 36,899 (d) 2,544 (a) 108,243 Cost of natural gas and electricity — 36,899 (36,899 ) (d) — General and administrative 17,380 — 5,394 (d) 22,774 Depreciation and amortization 6,789 — 2,299 (d) 2,119 (b) 11,207 Operating expenses — 7,693 (7,693 ) (d) — Total operating expenses 92,969 44,592 — 4,663 142,224 Operating income (loss) 17,577 6,552 — (4,663 ) 19,466 Other (expense)/income: Interest expense (753 ) (123 ) — — (876 ) Interest and other income (95 ) 11 — — (84 ) Total other expenses (848 ) (112 ) — — (960 ) Income (loss) before income tax expense 16,729 6,440 — (4,663 ) 18,506 Income tax expense 988 23 — 160 (c) 1,171 Net income (loss) 15,741 6,417 — (4,823 ) 17,335 Less: Net income (loss) attributable to non-controlling interests 11,568 — — (3,682 ) (f) 7,886 Net income (loss) attributable to Spark Energy, Inc. stockholders $ 4,173 $ 6,417 $ — $ (1,141 ) $ 9,449 Net income attributable to Spark Energy, Inc. per share of Class A common stock Basic $ 1.11 N/A $ 2.52 Diluted $ 0.68 N/A $ 0.66 Weighted average shares of Class A common stock Basic 3,756 N/A (e) 3,756 Diluted 14,520 N/A (e) 16,519 Notes to unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2016
Unaudited Pro Forma Condensed Combined Statement of Operations. For the Nine Months Ended September 30, 2022 (In thousands) Xtant (Historical) Surgalign SPV (Historical) Transaction Accounting Adjustments Notes Pro Forma Combined Revenue Orthopedic product sales $ 42,689 $ 10,931 $ — $ 53,620 Other revenue 10 — — 10 Total Revenue 42,699 10,931 — 53,630 Cost of sales 18,868 378 164 5(c) 19,410 Gross Profit 23,831 10,553 (164 ) 34,220 Operating Expenses General and administrative 11,496 253 1,130 5(e) 12,879 Sales and marketing 16,683 5,506 43 5(d) 22,232 Research and development 683 — — 683 Total Operating Expenses 28,862 5,759 1,173 35,794 (Loss) Income from Operations (5,031 ) 4,794 (1,337 ) (1,574 ) Other Expense Interest expense (1,197 ) — (189 ) 5(b) (1,386 ) Total Other Expense (1,197 ) — (189 ) (1,386 ) Net (Loss) Income from Operations Before Provision for Income Taxes (6,228 ) 4,794 (1,526 ) (2,960 ) Provision for Income Taxes Current and Deferred (48 ) — — (48 ) Net (Loss) Income $ (6,276 ) $ 4,794 $ (1,526 ) $ (3,008 ) Net Loss Per Share: Basic $ (0.07 ) $ (0.03 ) Dilutive $ (0.07 ) $ (0.03 ) Shares used in the computation: Basic 89,236,832 89,236,832 Dilutive 89,236,832 89,236,832 See notes to unaudited pro forma condensed combined financial statements.
Unaudited Pro Forma Condensed Combined Statement of Operations a. Represents purchase price adjustments for the acquisition of Turbo as follows:
